Literature DB >> 18336205

Artificial evolution with adeno-associated viral libraries.

Luca Perabo1, Anke Huber, Stephan Märsch, Michael Hallek, Hildegard Büning.   

Abstract

After attracting the attention of the scientific community due to a number of favourable characteristics that make it an attractive vector for human gene therapy [1,2], AAV has been thoroughly investigated in the past two decades. Standard technologies for the manipulation of the viral genome and for efficient packaging and purification protocols have paved the road for trial and error manipulation by educated guesses to study viral infectious biology by reverse genetics and to generate improved vectors for human gene transfer. However, despite remarkable progress, our limited knowledge of molecular mechanisms implicated in virus-cell interactions has been a limiting factor. Combinatorial engineering and high-throughput selection techniques hold the potential to boost technological improvement by offering the possibility to screen large numbers of randomly generated clones by appropriate selection protocols. These approaches not only require lesser knowledge of viral biology, but can also be employed as valuable tools to investigate molecular mechanisms that drive the infection process. In this review we recapitulate the rationale for employment of combinatorial methods in AAV vector development and the accomplishments achieved so far, discussing current limitations and interesting developments that are in sight.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18336205     DOI: 10.2174/138620708783744507

Source DB:  PubMed          Journal:  Comb Chem High Throughput Screen        ISSN: 1386-2073            Impact factor:   1.339


  8 in total

Review 1.  Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients.

Authors:  Pasqualina Colella; Alberto Auricchio
Journal:  Hum Gene Ther       Date:  2012-08       Impact factor: 5.695

2.  Pseudotyped adeno-associated viral vector tropism and transduction efficiencies in murine wound healing.

Authors:  Sundeep G Keswani; Swathi Balaji; Louis Le; Alice Leung; Foong-Yen Lim; Mounira Habli; Helen N Jones; James M Wilson; Timothy M Crombleholme
Journal:  Wound Repair Regen       Date:  2012-06-19       Impact factor: 3.617

3.  The extracellular matrix glycoprotein tenascin-C is beneficial for spinal cord regeneration.

Authors:  Jian Chen; Hyun Joon Lee; Igor Jakovcevski; Ronak Shah; Neha Bhagat; Gabriele Loers; Hsing-Yin Liu; Sally Meiners; Grit Taschenberger; Sebastian Kügler; Andrey Irintchev; Melitta Schachner
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

4.  Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.

Authors:  Eike Kienle; Elena Senís; Kathleen Börner; Dominik Niopek; Ellen Wiedtke; Stefanie Grosse; Dirk Grimm
Journal:  J Vis Exp       Date:  2012-04-02       Impact factor: 1.355

Review 5.  Clinical review: gene-based therapies for ALI/ARDS: where are we now?

Authors:  James Devaney; Maya Contreras; John G Laffey
Journal:  Crit Care       Date:  2011-06-20       Impact factor: 9.097

Review 6.  Human Immune Responses to Adeno-Associated Virus (AAV) Vectors.

Authors:  Giuseppe Ronzitti; David-Alexandre Gross; Federico Mingozzi
Journal:  Front Immunol       Date:  2020-04-17       Impact factor: 7.561

7.  Recombinant vectors based on porcine adeno-associated viral serotypes transduce the murine and pig retina.

Authors:  Agostina Puppo; Alexander Bello; Anna Manfredi; Giulia Cesi; Elena Marrocco; Michele Della Corte; Settimio Rossi; Massimo Giunti; Maria Laura Bacci; Francesca Simonelli; Enrico Maria Surace; Gary P Kobinger; Alberto Auricchio
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

Review 8.  Recent progress and considerations for AAV gene therapies targeting the central nervous system.

Authors:  Erik Allen Lykken; Charles Shyng; Reginald James Edwards; Alejandra Rozenberg; Steven James Gray
Journal:  J Neurodev Disord       Date:  2018-05-18       Impact factor: 4.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.